Karus Therapeutics
  • Home
  • About Karus
    • At a glance
    • Leadership
    • Investors
  • Research & Development
  • Partnering
  • Media Centre
    • Press Releases
    • Events
    • In the News
    • Publications
    • Abstracts
  • Contact Us
  • Menu Menu

Media Centre

Archive

All 99 /Abstracts 18 /Events 10 /In The News 7 /Press Releases 57 /Publications 23

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients…
28 April 2020/by circlek

Karus Therapeutics Announces New Data from Phase I Cancer Trial at AACR

Oxfordshire, UK, 27 April 2020 – Karus Therapeutics Ltd (‘Karus’),…
27 April 2020/by circlek

ASH Annual Meeting & Exposition

7-10 December 2019
ASH Annual Meeting & Exposition
Orlando,…
10 December 2019/by circlek

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma

Results of a First in Human, Dose Ascending, Phase I Study Examining…
10 December 2019/by circlek

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH

Oxfordshire, UK, 4 December 2019 – Karus Therapeutics Ltd (‘Karus’),…
4 December 2019/by circlek

Karus Therapeutics features in Biology Impacting Lives programme

Oxfordshire, UK, 11 October 2019 – Karus Therapeutics, a clinical-stage…
11 October 2019/by circlek

Karus Therapeutics Appoints Dr Stephen Shuttleworth as Chairman of Scientific Advisory Board

ANNOUNCEMENT

Oxfordshire, UK, 17 September 2019 – Karus…
17 September 2019/by circlek

Karus Therapeutics Strengthens Clinical Leadership Team with Appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer

Oxfordshire, UK, 17 July 2019 – Karus Therapeutics Ltd (‘Karus’),…
17 July 2019/by circlek

FASEB Ion Channel Regulation Conference: Molecules to Disease

7-12 July 2019
FASEB Ion Channel Regulation Conference: Molecules…
12 July 2019/by circlek

15-ICML International Conference on Malignant Lymphoma

18-22 June 2019
15-ICML International Conference on Malignant…
22 June 2019/by circlek

2018 Operational Update

Tim Edwards appointed as Executive Chairman
KA2237 and KA2507…
31 December 2018/by circlek

Genesis 2018

13 December 2018
Genesis 2018
London, UK
13 December 2018/by circlek

30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

13-16 November 2018
30th EORTC-NCI-AACR Symposium on Molecular…
16 November 2018/by circlek

BIO-Europe

5-7 November 2018
BIO-Europe
Copenhagen, Denmark & Malmö,…
7 November 2018/by circlek

NCRI Cancer Conference

4-6 November 2018
NCRI Cancer Conference
Glasgow, UK
6 November 2018/by circlek

BIA UK Bioscience Forum

18 October 2018
BIA UK Bioscience Forum
London, UK
18 October 2018/by circlek

ELRIG Drug Discovery 2018

9-10 October 2018
ELRIG Drug Discovery 2018
London, UK
10 October 2018/by circlek

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells…
8 June 2018/by circlek

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant effect in models of transplantation.

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant…
1 June 2018/by circlek

AACR Annual Meeting 2018

14-18 April 2018
AACR Annual Meeting 2018
Chicago, USA
Stephen…
18 April 2018/by circlek

Functional characterization of a novel somatic mutation of PIK3CB

Functional characterization of a novel somatic mutation of PIK3CB
Whale…
20 November 2017/by circlek

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Oxfordshire, UK, 18th September 2017 – Karus Therapeutics…
18 September 2017/by circlek

Karus Therapeutics presenting at the CHI DoT 11th Annual Next-Generation Histone Deacetylase Inhibitors conference

Oxford, UK, 4 August 2017 – Karus Therapeutics Ltd, a leader…
4 August 2017/by circlek

Karus Therapeutics presenting at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design

Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in…
1 May 2017/by circlek

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell…
1 April 2017/by circlek

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237…
3 December 2016/by circlek

Karus Therapeutics features in BioCentury Innovations

Oxford, UK, 4 November 2016 – Karus Therapeutics, a leader…
4 November 2016/by circlek

Karus Therapeutics presenting at BIO-Europe

Oxford, UK, 21 October 2016 – Karus Therapeutics Ltd, a leader…
21 October 2016/by circlek

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

First cohort of cancer patients has been dosed with Karus’s…
5 October 2016/by circlek

Karus Therapeutics giving lecture at BIO Investor

Oxford, UK, 3 October 2016 – Karus Therapeutics Ltd, a leader…
3 October 2016/by circlek

Karus Therapeutics giving lecture at 10th Annual Symposium – Next Generation Histone Deacetylase Inhibitors

Oxford, UK, 7 September 2016 – Karus Therapeutics, a leader…
7 September 2016/by circlek

Karus Therapeutics delivering lecture at 9th Annual Kinase Inhibitor Discovery conference

Oxford, UK, 1 September 2016 – Karus Therapeutics, a leader…
1 September 2016/by circlek

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (Mainz)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting…
10 May 2016/by circlek

Karus Therapeutics presenting at BioEquity 2016

Oxford, UK, 21 April 2016 - Karus Therapeutics, a leader in the…
21 April 2016/by circlek

KA2237 and KA2507. Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (New Orleans)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting…
16 April 2016/by circlek

Karus Therapeutics presenting at AACR Annual Meeting 2016

Oxford, UK, 29 March 2016– Karus Therapeutics, a leader in…
29 March 2016/by circlek

Karus Therapeutics presenting at BioTrinity 2016

Oxford, UK, 21 March 2016 – Karus Therapeutics, a leader in…
21 March 2016/by circlek

Karus Therapeutics presenting at Sachs 9th Annual European Life Science CEO Forum & Exhibition

Oxford, UK, 1 March 2016 – Karus Therapeutics, a leader in…
1 March 2016/by circlek

Karus Therapeutics Announces Strategic Collaboration with The University of Texas MD Anderson Cancer Center

Oxford, UK, 10 December 2015 – Karus Therapeutics (‘Karus’),…
10 December 2015/by circlek

Karus Therapeutics presenting at the 4th Annual Cancer BioPartnering & Investment Forum

Oxford, UK, 7 December 2015 – Karus Therapeutics, a leader…
7 December 2015/by circlek

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Orlando)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237…
5 December 2015/by circlek

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Brussels)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237…
4 December 2015/by circlek

Karus Therapeutics presenting at the 8th Annual Biotech Showcase 2016

Oxford, UK, 30th November 2015 – Karus Therapeutics, a leader…
30 November 2015/by circlek

Karus Therapeutics presenting at the 57th ASH Annual Meeting

Oxford, UK, 26th November 2015 – Karus Therapeutics, a leader…
26 November 2015/by circlek

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Boston)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237…
7 November 2015/by circlek

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (Boston)

Design and Development of a Novel HDAC6-Selective Inhibitor,…
6 November 2015/by circlek

Karus Therapeutics presenting at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development

Oxford, UK, 2 November 2015 – Karus Therapeutics, a leader…
2 November 2015/by circlek

Karus Therapeutics presenting AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oxford, UK, 4 October 2015 – Karus Therapeutics, a leader in…
4 October 2015/by circlek

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (New York)

Design and Development of a Novel HDAC6-Selective Inhibitor,…
18 September 2015/by circlek

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (New York)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237…
18 September 2015/by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers

Design and Development of a Novel Series of Orally-Active, Selective…
18 April 2015/by circlek

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors

Design and Development of a Novel Series of HDAC6-Selective Inhibitors…
18 April 2015/by circlek

Karus Therapeutics presenting at Sachs Immuno-oncology: BD&L and Investment Forum

Karus Therapeutics, a leader in the development of innovative…
15 April 2015/by circlek

Karus Therapeutics presenting at BioTrinity 2015

Simon Kerry, CEO of Karus Therapeutics, a leader in the development…
18 March 2015/by circlek

Karus Therapeutics presenting at AACR Annual Meeting 2015

Karus Therapeutics, a leader in the development of innovative…
18 March 2015/by circlek

Karus Therapeutics presenting at Biotech Showcase 2015

Dr Simon Kerry, CEO of Karus Therapeutics, a leader in the development…
19 December 2014/by circlek

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors…
3 November 2014/by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (NCRI Meeting)

Design and Development of a Novel Series of Orally-Active, Selective…
3 November 2014/by circlek

Karus Therapeutics Appoints New Head of Clinical Development and Head of Biology

Oxford, UK, 21 October 2014 – Karus Therapeutics, a leader…
21 October 2014/by circlek

Karus Therapeutics presenting at NCRI Cancer Conference

Stephen Shuttleworth, CSO of Karus Therapeutics, a leader in…
29 September 2014/by circlek

Karus Therapeutics presenting at SACHS Biotech in Europe Forum

Karus Therapeutics, a leader in the development of innovative…
8 September 2014/by circlek

Karus Therapeutics features in SciBX

Oxford, UK, 15 May 2014 – Karus Therapeutics, a leader in the…
15 May 2014/by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (San Diego)

Design and Development of a Novel Series of Orally-Active, Selective…
5 April 2014/by circlek

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer

Design and Development of a Novel Series of HDAC6-Selective Inhibitors…
5 April 2014/by circlek

Karus Therapeutics presenting at AACR Annual Meeting 2014

Oxford, UK, 3 April 2014 – Karus Therapeutics, a leader in…
3 April 2014/by circlek

Karus Therapeutics showcased in BVCA’s Britain’s Hot Talents 2014/15

Oxford, UK, February 2014 – Karus Therapeutics, a leader in…
25 February 2014/by circlek

Karus Therapeutics Appoints Penelope Ward as CMO

Oxford, UK, 12 November 2013 – Karus Therapeutics, a leader…
12 November 2013/by circlek

Karus Therapeutics wins ‘Best Biotech Fundraiser’ award

Oxford, UK, 2 October 2013 – Karus Therapeutics, a leader in…
2 October 2013/by circlek

Karus Therapeutics shortlisted for key industry award

Oxford, UK, 26 September 2013 – Karus Therapeutics, a leader…
26 September 2013/by circlek

Karus Therapeutics secures prominent role in epigenetics debate at SciBX Summit 2013

Oxford, UK, 21 August 2013 – Karus Therapeutics, a leader in…
21 August 2013/by circlek

Karus Therapeutics interviewed by Pharma Television

Oxford, UK, 17 July 2013 – Karus Therapeutics, a leader in…
17 July 2013/by circlek

Karus Therapeutics features on BBC South News

Oxford, UK, 15 May 2013 – Karus Therapeutics, a leader in the…
15 May 2013/by circlek

Karus Therapeutics presenting at BIO, BioTrinity, Anglo-Nordic Biotech and Next-Gen Kinase Inhibitors

Oxford, UK, 19 April 2013 – Karus Therapeutics, a leader in…
19 April 2013/by circlek

Karus Therapeutics appoints Scientific Advisory Board and announces move to new Oxford facilities

Oxford, UK, 9 April 2013 – Karus Therapeutics, a leader in…
9 April 2013/by circlek

Collaboration with Babraham Institute to explore PI3 kinase inhibitors in the treatment of inflammatory diseases

Southampton, UK, 17 December 2012 – Karus Therapeutics, a leader…
17 December 2012/by circlek

Karus Therapeutics secures Series B financing from a syndicate of leading VC investors

Southampton, UK, 6 September 2012 – Karus Therapeutics, a leader…
6 September 2012/by circlek

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Progress in the preclinical discovery and clinical development…
1 January 2011/by circlek

Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.

Progress in the development of small molecule therapeutics targeting…
1 January 2011/by circlek

Karus Therapeutics secures further financing

Southampton, UK - 4 May 2010 - Innovative pharmaceutical company…
4 May 2010/by circlek

Karus develops new family of HDAC-6 selective inhibitors

Chilworth, UK - 18 February 2010 - Karus Therapeutics Ltd, a…
18 February 2010/by circlek

Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.

Histone Deacetylase inhibitors: new promise in the treatment…
1 January 2010/by circlek

Karus Therapeutics and Queen Mary, University of London announce PI3 kinase collaboration

Chilworth, UK - 23 September 2009 - Karus Therapeutics Ltd, a…
23 September 2009/by circlek

Karus CSO to present at three industry conferences

Chilworth, UK - 17 August 2009 - Innovative pharmaceutical company…
17 August 2009/by circlek

Organ transplant rejection collaboration with University Hospital Birmingham

Chilworth, UK - 1 June 2009 - Innovative pharmaceutical company…
1 June 2009/by circlek

KTP award with King’s College

Chilworth, UK - 4 May 2009 - Innovative pharmaceutical company…
4 May 2009/by circlek

Karus announces second closing of investment

Chilworth, UK - 6 April 2009 - Innovative pharmaceutical company…
6 April 2009/by circlek

Karus Therapeutics secures investment

Southampton, UK - 7 January 2009 - Innovative pharmaceutical…
7 January 2009/by circlek

Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.

Progress in the design and development of phosphoinositide 3-kinase…
1 January 2009/by circlek

Karus CSO presents at major industry conference

Southampton, UK - 20 October 2008 - Innovative pharmaceutical…
20 October 2008/by circlek

Karus CEO talks to Pharma TV

Karus CEO talks to Pharma TV
1 July 2008/by circlek

Ann Hacker joins Karus board

Southampton, UK - 2 April 2008 - Innovative pharmaceutical company…
2 April 2008/by circlek

Karus appoints Stephen Shuttleworth as Chief Scientific Officer

Southampton, UK - 1 January 2008 - Innovative pharmaceutical…
1 January 2008/by circlek

Karus Scientist presents at key industry conferences

Southampton, UK - 23 October 2007 - Innovative pharmaceutical…
23 October 2007/by circlek

Karus signs co-development agreement with EOS

Southampton, UK - 1 October 2007 - Innovative pharmaceutical…
1 October 2007/by circlek

Karus raises £0.82 million investment

Southampton, UK - 1 July 2007 - Innovative pharmaceutical company…
1 July 2007/by circlek

Drummond Paris named as Chairman of Karus Therapeutics

Southampton, UK - 12 October 2006 - Innovative biopharmaceutical…
12 October 2006/by circlek

Karus Therapeutics appoints Simon Kerry as CEO

Southampton, UK - 2 May 2006 - Karus Therapeutics, an emerging…
2 May 2006/by circlek

Collaboration with Sareum Holdings

Southampton, UK - 13 December 2005 - Karus Therapeutics is pleased…
13 December 2005/by circlek

Cancer and heart disease drug discovery company is latest spin-out from Southampton University

Southampton, UK - 21 July 2005 - A new spin-out company from…
21 July 2005/by circlek

  • Privacy Policy

© Karus Therapeutics. All rights reserved

Registered in England & Wales No 05490954
VAT No 871 4126 33

LinkedIn

Created by Instinctif Partners

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only